Poloxamer

Last updated
General structure
with a = 2-130 and b = 15-67 Poloxamere General Formula V2.svg
General structure
with a = 2–130 and b = 15–67

Poloxamers are nonionic triblock copolymers composed of a central hydrophobic chain of polyoxypropylene (poly(propylene oxide)) flanked by two hydrophilic chains of polyoxyethylene (poly(ethylene oxide)). The word poloxamer was coined by BASF inventor, Irving Schmolka, who received the patent for these materials in 1973. [1] Poloxamers are also known by the trade names Pluronic, [2] Kolliphor (pharma grade), [3] and Synperonic. [4]

Contents

Because the lengths of the polymer blocks can be customized, many different poloxamers exist that have slightly different properties. For the generic term poloxamer, these copolymers are commonly named with the letter P (for poloxamer) followed by three digits: the first two digits multiplied by 100 give the approximate molecular mass of the polyoxypropylene core, and the last digit multiplied by 10 gives the percentage polyoxyethylene content (e.g. P407 = poloxamer with a polyoxypropylene molecular mass of 4000 g/mol and a 70% polyoxyethylene content). For the Pluronic and Synperonic tradenames, coding of these copolymers starts with a letter to define its physical form at room temperature (L = liquid, P = paste, F = flake (solid)) followed by two or three digits, The first digit (two digits in a three-digit number) in the numerical designation, multiplied by 300, indicates the approximate molecular weight of the hydrophobe; and the last digit x 10 gives the percentage polyoxyethylene content (e.g., L61 indicates a polyoxypropylene molecular mass of 1800 g/mol and a 10% polyoxyethylene content). In the example given, poloxamer 181 (P181) = Pluronic L61 and Synperonic PE/L 61.

Micellization and phase transitions

An important characteristic of poloxamer solutions is their temperature dependent self-assembling and thermo-gelling behavior. Concentrated aqueous solutions of poloxamers are liquid at low temperature and form a gel at higher temperature in a reversible process. The transitions that occur in these systems depend on the polymer composition (molecular weight and hydrophilic/hydrophobic molar ratio).

At low temperatures and concentrations (below the critical micelle temperature and critical micelle concentration) individual block copolymers (unimers) are present in solution. Above these values, aggregation of individual unimers occurs in a process called micellization. This aggregation is driven by the dehydration of the hydrophobic polyoxypropylene block that becomes progressively less soluble as the polymer concentration or temperature increases. The aggregation of several unimers occurs to minimize the interactions of the PPO blocks with the solvent. Thus, the core of the aggregates is made from the insoluble blocks (polyoxypropylene) while the soluble portion (polyoxyethylene) forms the shell of the micelles.

The mechanisms on the micellization at equilibrium have shown to depend on two relaxation times: (1) the first and fastest (tens of the microseconds scale) corresponds to the unimers exchange between micelles and the bulk solution and follows the Aniansson-Wall model (step-by-step insertion and expulsion of single polymer chains), [5] and (2) the second and much slower one (in the millisecond range) is attributed to the formation and breakdown of whole micellar units leading to the final micellar size equilibration.

Besides spherical micelles, elongated or worm-like micelles can also be formed. The final geometry will depend on the entropy costs of stretching the blocks, which is directly related to their composition (size and polyoxypropylene/polyoxyethylene ratio). [6] The mechanisms involved in the shape transformation are different compared to the dynamics of micellization. Two mechanisms were proposed for the sphere-to-rod transitions of block copolymer micelles, in which the micellar growth can occur by (A) fusion/fragmentation of micelles or (B) concomitant fusion/fragmentation of micelles and unimer exchange, followed by smoothing of the rod-like structures. [7]

With higher increments of the temperature and/or concentration, other phenomena can occur such as the formation of highly ordered mesophases (cubic, hexagonal and lamellar). Eventually, a complete dehydration of the polyoxypropylene blocks and the collapse of the polyoxyethylene chains will lead to clouding and/or macroscopic phase separation. This is due to the fact that hydrogen bonding between the polyoxyethylene and the water molecules breaks down at high temperature and polyoxyethylene becomes also insoluble in water.

The phase transitions can also be largely influenced by the use of additives such as salts and alcohols. The interactions with salts are related to their ability to act as water structure makers (salting-out) or water structure breakers (salting-in). Salting-out salts increase the self-hydration of water through hydrogen bonding and reduce the hydration of the copolymers, thus reducing the critical micelle temperature and critical micelle concentration. Salting-in electrolytes reduce the water self-hydration and increase the polymer hydration, therefore increasing the critical micelle temperature and critical micelle concentration. The different salts have been categorized by the Hofmeister series according to their ‘salting-out’ power. Different phase diagrams characterizing all these transitions have been constructed for most poloxamers using a great variety of experimental techniques (e.g. SAXS, Differential scanning calorimetry, viscosity measurements, light scattering).

Uses

Because of their amphiphilic structures, the polymers have surfactant properties that make them useful in industrial applications. Among other things, they can be used to increase the water solubility of hydrophobic, oily substances or otherwise increase the miscibility of two substances with different hydrophobicities. For this reason, these polymers are commonly used in industrial applications, cosmetics, and pharmaceuticals. They have also been evaluated for various drug delivery applications and were shown to sensitize drug-resistant cancers to chemotherapy.

In bioprocess applications, poloxamers are used in cell culture media for their cell cushioning effects because their addition leads to less stressful shear conditions for cells in reactors. There are grades of poloxamers commercially available specifically for cell culture, including Kolliphor P 188 Bio. [8]

In materials science, the poloxamer P123 has recently been used in the synthesis of mesoporous materials, including SBA-15.

When mixed with water, concentrated solutions of poloxamers can form hydrogels. These gels can be extruded easily, acting as a carrier for other particles, and used for robocasting. [9]

Biological effect

Work led by Kabanov has recently shown that some of these polymers, originally thought to be inert carrier molecules, have a very real effect on biological systems independently of the drug they are transporting. [10] [11] [12] [13] The poloxamers have been shown to incorporate into cellular membranes affecting the microviscosity of the membranes. The polymers seem to have the greatest effect when absorbed by the cell as an unimer rather than as a micelle. [14]

On multi drug resistant cancer cells

Poloxamers have been shown to preferentially target cancer cells, due to differences in the membrane of these cells when compared to noncancer cells. Poloxamers have also been shown to inhibit MDR proteins and other drug efflux transporters on the surface of cancer cells; the MDR proteins are responsible for the efflux of drugs from the cells and hence increase the susceptibility of cancer cells to chemotherapeutic agents such as doxorubicin.

Another effect of the polymers upon cancer cells is the inhibition of the production of ATP in multi-drug resistant (MDR) cancer cells. The polymers seem to inhibit respiratory proteins I and IV, and the effect on respiration seems to be selective for MDR cancer cells, which may be explained by the difference in fuel sources between MDR and sensitive cells (fatty acids and glucose respectively).

The poloxamers have also been shown to enhance proto-apoptotic signaling, decrease anti-apoptoic defense in MDR cells, inhibit the glutathione/glutathione S-transferase detoxification system, induce the release of cytochrome C, increase reactive oxygen species in the cytoplasm, and abolish drug sequestering within cytoplasmic vesicles.

On nuclear factor kappa B

Certain poloxamers such as P85 have been shown not only to be able to transport target genes to target cells, but also to increase gene expression. Certain poloxamers, such as P85 and L61, have also been shown to stimulate transcription of NF kappaB genes, although the mechanism by which this is achieved is currently unknown, bar that P85 has been shown to induce phosphorylation of the inhibitory kappa.

Potential degradation by sonication

Wang et al. reported that aqueous solutions of poloxamer 188 (Pluronic F-68) and poloxamer 407 (Pluronic F-127) sonicated in the presence or absence of multi-walled carbon nanotubes (MWNTs) can became highly toxic to cultured cells. Moreover, toxicity correlated with the sonolytic degradation of the polymers. [15]

Related Research Articles

<span class="mw-page-title-main">Micelle</span> Group of fatty molecules suspended in liquid by soaps and/or detergents

A micelle or micella is an aggregate of surfactant amphipathic lipid molecules dispersed in a liquid, forming a colloidal suspension. A typical micelle in water forms an aggregate with the hydrophilic "head" regions in contact with surrounding solvent, sequestering the hydrophobic single-tail regions in the micelle centre.

<span class="mw-page-title-main">Copolymer</span> Polymer derived from more than one species of monomer

In polymer chemistry, a copolymer is a polymer derived from more than one species of monomer. The polymerization of monomers into copolymers is called copolymerization. Copolymers obtained from the copolymerization of two monomer species are sometimes called bipolymers. Those obtained from three and four monomers are called terpolymers and quaterpolymers, respectively. Copolymers can be characterized by a variety of techniques such as NMR spectroscopy and size-exclusion chromatography to determine the molecular size, weight, properties, and composition of the material.

<span class="mw-page-title-main">PLGA</span> Copolymer of varying ratios of polylactic acid and polyglycolic acid

PLGA, PLG, or poly(lactic-co-glycolic acid) is a copolymer which is used in a host of Food and Drug Administration (FDA) approved therapeutic devices, owing to its biodegradability and biocompatibility. PLGA is synthesized by means of ring-opening co-polymerization of two different monomers, the cyclic dimers (1,4-dioxane-2,5-diones) of glycolic acid and lactic acid. Polymers can be synthesized as either random or block copolymers thereby imparting additional polymer properties. Common catalysts used in the preparation of this polymer include tin(II) 2-ethylhexanoate, tin(II) alkoxides, or aluminum isopropoxide. During polymerization, successive monomeric units are linked together in PLGA by ester linkages, thus yielding a linear, aliphatic polyester as a product.

Poloxamer 407 is a hydrophilic non-ionic surfactant of the more general class of copolymers known as poloxamers. Poloxamer 407 is a triblock copolymer consisting of a central hydrophobic block of polypropylene glycol flanked by two hydrophilic blocks of polyethylene glycol (PEG). The approximate lengths of the two PEG blocks is 101 repeat units, while the approximate length of the propylene glycol block is 56 repeat units. This particular compound is also known by the BASF trade name Pluronic F-127 or by the Croda trade name Synperonic PE/F 127. BASF also offers a pharmaceutical grade, under trade name Kolliphor P 407.

A drug carrier or drug vehicle is a substrate used in the process of drug delivery which serves to improve the selectivity, effectiveness, and/or safety of drug administration. Drug carriers are primarily used to control the release of drugs into systemic circulation. This can be accomplished either by slow release of a particular drug over a long period of time or by triggered release at the drug's target by some stimulus, such as changes in pH, application of heat, and activation by light. Drug carriers are also used to improve the pharmacokinetic properties, specifically the bioavailability, of many drugs with poor water solubility and/or membrane permeability.

Poly(N-isopropylacrylamide) (variously abbreviated PNIPA, PNIPAM, PNIPAAm, NIPA, PNIPAA or PNIPAm) is a temperature-responsive polymer that was first synthesized in the 1950s. It can be synthesized from N-isopropylacrylamide which is commercially available. It is synthesized via free-radical polymerization and is readily functionalized making it useful in a variety of applications.

Pluronic P123 is a symmetric triblock copolymer comprising poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO) in an alternating linear fashion, PEO-PPO-PEO. The unique characteristic of PPO block, which is hydrophobic at temperatures above 288 K and is soluble in water at temperatures below 288 K, leads to the formation of micelle consisting of PEO-PPO-PEO triblock copolymers. Some studies report that the hydrophobic core contains PPO block, and a hydrophilic corona consists of PEO block. In 30wt% aqueous solution Pluronic P123 forms a cubic gel phase.

<span class="mw-page-title-main">Polylysine</span> Chemical compound

Polylysine refers to several types of lysine homopolymers, which may differ from each other in terms of stereochemistry and link position (α/ε). Of these types, only ε-poly-L-lysine is produced naturally.

A nanogel is a polymer-based, crosslinked hydrogel particle on the sub-micron scale. These complex networks of polymers present a unique opportunity in the field of drug delivery at the intersection of nanoparticles and hydrogel synthesis. Nanogels can be natural, synthetic, or a combination of the two and have a high degree of tunability in terms of their size, shape, surface functionalization, and degradation mechanisms. Given these inherent characteristics in addition to their biocompatibility and capacity to encapsulate small drugs and molecules, nanogels are a promising strategy to treat disease and dysfunction by serving as delivery vehicles capable of navigating across challenging physiological barriers within the body. 

In colloidal chemistry, the critical micelle concentration (CMC) of a surfactant is one of the parameters in the Gibbs free energy of micellization. The concentration at which the monomeric surfactants self-assemble into thermodynamically stable aggregates is the CMC. The Krafft temperature of a surfactant is the lowest temperature required for micellization to take place. There are many parameters that affect the CMC. The interaction between the hydrophilic heads and the hydrophobic tails play a part, as well as the concentration of salt within the solution and surfactants.

<span class="mw-page-title-main">Nanocarrier</span>

A nanocarrier is nanomaterial being used as a transport module for another substance, such as a drug. Commonly used nanocarriers include micelles, polymers, carbon-based materials, liposomes and other substances. Nanocarriers are currently being studied for their use in drug delivery and their unique characteristics demonstrate potential use in chemotherapy. This class of materials was first reported by a team of researchers of University of Évora, Alentejo in early 1960's, and grew exponentially in relevance since then.

The behavior of quantum dots (QDs) in solution and their interaction with other surfaces is of great importance to biological and industrial applications, such as optical displays, animal tagging, anti-counterfeiting dyes and paints, chemical sensing, and fluorescent tagging. However, unmodified quantum dots tend to be hydrophobic, which precludes their use in stable, water-based colloids. Furthermore, because the ratio of surface area to volume in a quantum dot is much higher than for larger particles, the thermodynamic free energy associated with dangling bonds on the surface is sufficient to impede the quantum confinement of excitons. Once solubilized by encapsulation in either a hydrophobic interior micelle or a hydrophilic exterior micelle, the QDs can be successfully introduced into an aqueous medium, in which they form an extended hydrogel network. In this form, quantum dots can be utilized in several applications that benefit from their unique properties, such as medical imaging and thermal destruction of malignant cancers.

Timothy P. Lodge is an American polymer scientist.

Elastin-like polypeptides (ELPs) are synthetic biopolymers with potential applications in the fields of cancer therapy, tissue scaffolding, metal recovery, and protein purification. For cancer therapy, the addition of functional groups to ELPs can enable them to conjugate with cytotoxic drugs. Also, ELPs may be able to function as polymeric scaffolds, which promote tissue regeneration. This capacity of ELPs has been studied particularly in the context of bone growth. ELPs can also be engineered to recognize specific proteins in solution. The ability of ELPs to undergo morphological changes at certain temperatures enables specific proteins that are bound to the ELPs to be separated out from the rest of the solution via experimental techniques such as centrifugation.

Cancer treatments may vary depending on what type of cancer is being targeted, but one challenge remains in all of them: it is incredibly difficult to target without killing good cells. Cancer drugs and therapies all have very low selective toxicity. However, with the help of nanotechnology and RNA silencing, new and better treatments may be on the horizon for certain forms of cancer.

Nanoparticle drug delivery systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. The modern form of a drug delivery system should minimize side-effects and reduce both dosage and dosage frequency. Recently, nanoparticles have aroused attention due to their potential application for effective drug delivery.

<span class="mw-page-title-main">Dextran drug delivery systems</span> Polymeric drug carrier

Dextran drug delivery systems involve the use of the natural glucose polymer dextran in applications as a prodrug, nanoparticle, microsphere, micelle, and hydrogel drug carrier in the field of targeted and controlled drug delivery. According to several in vitro and animal research studies, dextran carriers reduce off-site toxicity and improve local drug concentration at the target tissue site. This technology has significant implications as a potential strategy for delivering therapeutics to treat cancer, cardiovascular diseases, pulmonary diseases, bone diseases, liver diseases, colonic diseases, infections, and HIV.

Pullulan bioconjugates are systems that use pullulan as a scaffold to attach biological materials to, such as drugs. These systems can be used to enhance the delivery of drugs to specific environments or the mechanism of delivery. These systems can be used in order to deliver drugs in response to stimuli, create a more controlled and sustained release, and provide a more targeted delivery of certain drugs.

<span class="mw-page-title-main">Reduction-sensitive nanoparticles</span> Drug delivery method

Reduction-sensitive nanoparticles (RSNP) consist of nanocarriers that are chemically responsive to reduction. Drug delivery systems using RSNP can be loaded with different drugs that are designed to be released within a concentrated reducing environment, such as the tumor-targeted microenvironment. Reduction-Sensitive Nanoparticles provide an efficient method of targeted drug delivery for the improved controlled release of medication within localized areas of the body.

<span class="mw-page-title-main">Alexander Kabanov (chemist)</span>

Alexander Viktorovich Kabanov, is a Russian and American chemist, an educator, an entrepreneur, and a researcher in the fields of drug delivery and nanomedicine.

References

  1. US 3740421,Schmolka IR,"Polyoxyethylene-polyoxypropylene aqueous gels",published 1973-06-19, assigned to BASF Wyandotte Corp.
  2. "BASF - Product information the chemicals catalog - Pluronics". BASF Corporation Website. Retrieved 2008-12-09.
  3. "Poloxamers". BASF Pharma Solutions.
  4. "Synperonic". Croda.
  5. Aniansson EA, Wall SN (May 1974). "Kinetics of step-wise micelle association". The Journal of Physical Chemistry. 78 (10): 1024–1030. doi:10.1021/j100603a016.
  6. Alexandridis P, Hatton T (March 1995). "Poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) block copolymer surfactants in aqueous solutions and at interfaces: thermodynamics, structure, dynamics, and modeling". Colloids and Surfaces A. 96 (1–2): 1–46. doi:10.1016/0927-7757(94)03028-X.
  7. Denkova AG, Mendes E, Coppens MO (2010). "Non-equilibrium dynamics of block copolymer micelles in solution: recent insights and open questions". Soft Matter. 6 (11): 2351–2357. Bibcode:2010SMat....6.2351D. doi:10.1039/C001175B.
  8. "Poloxamers for Pharmaceutical Applications". BASF Pharma. Retrieved 2022-06-11.
  9. Feilden E (2016). "Robocasting of structural ceramic parts with hydrogel inks". Journal of the European Ceramic Society. 36 (10): 2525–2533. doi:10.1016/j.jeurceramsoc.2016.03.001. hdl: 10044/1/29973 .
  10. Pitto-Barry A, Barry NP (2014-04-15). "Pluronic® block-copolymers in medicine: from chemical and biological versatility to rationalisation and clinical advances". Polymer Chemistry. 5 (10): 3291–3297. doi:10.1039/C4PY00039K. hdl: 10454/11223 . ISSN   1759-9962. S2CID   98592847.
  11. Li J, Yu F, Chen Y, Oupický D (December 2015). "Polymeric drugs: Advances in the development of pharmacologically active polymers". Journal of Controlled Release. 219: 369–382. doi:10.1016/j.jconrel.2015.09.043. PMC   4656093 . PMID   26410809.
  12. Nugraha DH, Anggadiredja K, Rachmawati H (2023-01-16). "Mini-Review of Poloxamer as a Biocompatible Polymer for Advanced Drug Delivery". Brazilian Journal of Pharmaceutical Sciences. 58. doi: 10.1590/s2175-97902022e21125 . ISSN   2175-9790. S2CID   256177315.
  13. de Castro KC, Coco JC, Dos Santos ÉM, Ataide JA, Martinez RM, do Nascimento MH, et al. (December 2022). "Pluronic® triblock copolymer-based nanoformulations for cancer therapy: A 10-year overview". Journal of Controlled Release. 353: 802–822. doi:10.1016/j.jconrel.2022.12.017. PMID   36521691. S2CID   254851024.
  14. Batrakova EV, Kabanov AV (September 2008). "Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers". Journal of Controlled Release. 130 (2): 98–106. doi:10.1016/j.jconrel.2008.04.013. PMC   2678942 . PMID   18534704.
  15. Wang R, Hughes T, Beck S, Vakil S, Li S, Pantano P, Draper RK (November 2013). "Generation of toxic degradation products by sonication of Pluronic® dispersants: implications for nanotoxicity testing". Nanotoxicology. 7 (7): 1272–1281. doi:10.3109/17435390.2012.736547. PMC   3657567 . PMID   23030523.

Further reading